Minerva announces publication of roluperidone Phase 2B trial results
Minerva Neurosciences announced that The Journal of Clinical Psychiatry has published online results demonstrating cognitive improvements in patients with schizophrenia treated with roluperidone, or MIN-101. The results also demonstrated that cognitive improvements correlate with previously reported improvements in negative symptoms. The manuscript is entitled "Cognitive Effects of MIN-101 in Patients with Schizophrenia and Negative Symptoms: Results from a Randomized Controlled Trial." Roluperidone is a novel compound with affinities for 5HT2A and sigma2 receptors and no direct binding to dopamine receptors. In this regard, roluperidone differs from drugs currently indicated for schizophrenia, all of which directly interfere with dopamine neurotransmission. Results presented in this publication suggest a benefit of roluperidone on cognitive performance in schizophrenia patients with stable positive symptoms and moderate to severe negative symptoms. Researchers hypothesized that because roluperidone lacks the detrimental effects associated with currently available medications that do not benefit cognitive performance in patients with schizophrenia, the potential beneficial effects on cognition induced by 5HT2A antagonism and sigma antagonism would not be disrupted or diminished by other aspects of the compound's mechanism of action.